Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 4;7:16837. doi: 10.1038/s41598-017-17082-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Overall structures of the PPARγ LBD complexed with pioglitazone and lobeglitazone. (A) Chemical structures of pioglitazone, rosiglitazone, and lobeglitazone. Structurally conserved parts of TZDs are shaded with light blue colors. (B) Monomeric structure of the PPARγ LBDs complexed with lobeglitazone. The C-terminal AF-2 helix (H12) is colored in red. The disordered Ω-loops are indicated with dashed lines. The bound ligands are shown as transparent spheres. (C) Monomeric structure of the PPARγ LBDs complexed with pioglitazone. (D) The PPARγ LBD crystallized as a homo-dimer composed of active and inactive forms in an asymmetric unit. (E) Structural superposition of A and B chains of the lobeglitazone-bound PPARγ LBD. (F) Structural comparison of the lobeglitazone- and pioglitazone-bound PPARγ LBDs.